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Abstract: Primary splenic lymphoma (PSL) is a rare malignancy representing about 1% of all lym-
phoproliferative disorders, when using a strict definition that allows only involvement of spleen
and hilar lymph nodes. In contrast, secondary low-grade B-cell lymphomas in the spleen, such
as follicular lymphomas (FL), lymphoplasmacytic lymphoma and chronic lymphocytic leukemia/
small lymphocytic lymphoma, particularly as part of advanced stage disease, are more common.
Indolent B cell lymphomas expressing CD10 almost always represent FL, which in its primary
splenic form is the focus of this review. Primary splenic follicular lymphoma (PSFL) is exceedingly
infrequent. This type of lymphoproliferative disorder is understudied and, in most cases, clinically
characterized by splenomegaly or cytopenias related to hypersplenism. The diagnosis requires
correlation of histopathology of spleen, blood and/or bone marrow with the correct immunopheno-
type (determined by flow cytometry and/or immunohistochemistry) and if necessary, additional
molecular profiling. Management of this incurable disease is evolving, and splenectomy remains the
mainstream treatment for stage I PSFL.
Keywords: low-grade B-cell lymphomas; follicular lymphoma; primary splenic follicular lymphoma
1. Introduction
Neprilysin (CD10) is a cell surface zinc-dependent metalloendopeptidase expressed
in normal and neoplastic hematopoietic and non-hematopoietic tissue [1]. This protein
was first identified in kidney and found afterwards to be also expressed widely in other
tissues using immunohistochemistry [2,3]. The protein expression profile of CD10, includes
frequently lymphoblasts from children with acute lymphoblastic leukemia (ALL), which
led to the descriptor of Common ALL Antigen (CALLA) for this enzyme. In hematopoietic
tissue, CD10 is detected in lymphocytes (in a maturation dependent fashion) and neu-
trophils [3]. Benign and neoplastic B cells of germinal center derivation, and immature
lymphoid cells are positive for CD10. Therefore, detection of this antigen (in conjunction
with CD5 and CD23) is invaluable for the classification of mature and immature lymphoid
neoplasms (see below) and was used (together with CD5) to organize this review series
(Aggarwal, Auerbach, Gomes da Silva Cross Reference). Besides its crucial diagnostic value,
the potential prognostic role of CD10 expression was recognized early [4]. Therefore, CD10
constitutes a canonical element of current subclassification and prognostic algorithms in
diffuse large B cell lymphoma (DLBCL), where its expression generally predicts more favor-
able outcomes [5]. However, CD10 cannot be used alone for independent prognostication
of low-grade B cell lymphoma.
CD10 expression together with light chain restriction (monoclonality) in a low-grade
B-cell population supports the diagnosis of follicular lymphoma (FL), a very common
Curr. Oncol. 2021, 28, 4821–4831. https://doi.org/10.3390/curroncol28060407 https://www.mdpi.com/journal/curroncol
Curr. Oncol. 2021, 28 4822
disease accounting for 10 to 20% of all lymphomas in the Western world. However, CD10
positivity cannot be used in isolation for the diagnosis of FL, since tumor expression varies
depending on the idiosyncrasy and the topography of the neoplasm. For instance, CD10
expression was present in 77% of 127 cases of FL diagnosed in a subspecialized pathology
consultation service [6]. Furthermore, high-grade lymphomas/leukemias, such as DLBCL
or Burkitt lymphoma (BL) are also classically positive for CD10. In addition, lymphomas
that are typically negative for CD10, including marginal zone lymphoma (MZL), hairy cell
leukemia (HCL) and lymphoplasmacytic lymphomas (LPL), can occasionally be reactive for
this antigen [7]. Finally, very rare instances of CD5/CD10-double positive B cell lymphomas
have been reported [8]. Therefore, integration of clinicopathologic data is necessary for an
accurate diagnosis of lymphomas, including multiparametric marker evaluation where
CD10 expression is a critical value.
Follicular lymphoma (FL) is a mature B-cell non-Hodgkin lymphoma derived from
germinal center B-lymphocytes (centrocytes and centroblasts) that generally has at least
a partially follicular/nodular histologic pattern [9]. Nodal disease is most common, and
extension to any extranodal site may ensue [10]. Lymphomatous involvement of bone
marrow, peripheral blood, and spleen (seen in 20% of cases) is more common than infil-
tration of the Waldeyer ring or other extranodal presentation [11]. Four variants of FL are
distinguished in the current WHO classification of 2017, namely in situ follicular neoplasia
(presenting at any site), duodenal type FL, testicular FL, and diffuse FL (showing a pre-
dominantly diffuse growth pattern and lacking the distinguishing IGH/BCL2 chromosomal
translocation). In addition, primary cutaneous follicle center lymphoma (formerly called
Crosti lymphoma) is recognized as a distinct entity, which usually affects skin of the head or
trunk [7]. FL manifesting as primary splenic lymphoma (PSL) is very rare, and therefore its
clinicopathologic features are still not well established. Since several reviews are published
every year on FL, this article will focus on indolent primary FL of the spleen (subsequently
abbreviated as PSFL), an uncommon and understudied lymphoproliferative disorder.
A literature review highlighting unique characteristics and therapeutic management
of PSFL will be presented in the following sections.
2. Epidemiology
PSL comprise approximately 1% of all malignant neoplasms [12,13], when the disease
is restricted to involvement of the spleen and hilar lymph nodes. However, a broader
definition also encompassing liver, bone marrow or peripheral blood involvement, but
lacking prominent distant adenopathy, is accepted as well.
Epidemiologically, one study showed the prevalence of PSL to be approximately
62%, where DLBCL was the most common lymphoid neoplasm (25%) followed by splenic
MZL (15%) and FL (6%) [14]. Low-grade CD10-positive lymphoproliferative disorders
encountered in splenic specimens belong most frequently to the category of FL (either
primary or secondary). However, a subset of FL in the spleen represents aggressive disease
(equivalent to DLBCL), considering that extranodal FL is most commonly a high-grade
lymphoma that may lack expression (or translocation) of BCL2 [15,16]. However, duodenal-
type FL represents an exception to this rule, due to an indolent course and constant
expression of BCL2 [9].
The incidence of PSFL is unknown and may be overestimated because the vast majority
of FL in the spleen represent secondary disease. In general, PSFL accounts for a small
fraction of PSL and only a few case series are available on this entity [17–19].
In general, FL has an incidence of 2.1 per in the United States (SEER Follicular
Lymphoma—Cancer Stat Facts (https://seer.cancer.gov/statfacts/html/follicular.html,
accessed 16 October 2021), and is less common in eastern Europe, Asia and developing
countries [7]. FL is 2–3 times more common in white than in black patients [9,20], and
disproportionately affects females. The mean age at diagnosis (including all histologic
grades) has been estimated to be 68 years, which is similar to nodal FL [17,18,21–23]. PSFL
is rarely seen in patients younger than 50 years based on case series [17,18,22].
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3. Clinical Presentation
Due to the rarity of PSFL, clinical features are incompletely defined. In contrast to
nodal FL, most patients present with stage I/II disease [23]. A minority of cases show
bone marrow, peripheral blood or liver infiltration [18]. In PSFL, isolated splenomegaly
either asymptomatic or accompanied by upper abdominal discomfort is the rule [18].
B symptoms occur in a minority (less than 20%) of cases. Cytopenias (anemia and/or
thrombocytopenia) secondary to hypersplenism or rarely due to bone marrow infiltration
have been reported [18,22]. In contrast, nodal FL, which may involve the spleen, is usually
accompanied by distant lymphadenopathy and more frequent systemic symptoms. The real
frequency of PSFL remains to be established. As such, the disease may be incidentally found
during work up for other medical conditions [24]. However, pathologic splenic rupture
due to massive splenomegaly has been described [25]. Atypical lymphocytosis observed
in peripheral blood smears or liver biopsies and/or mild to moderate splenomegaly may
be identified incidentally during clinical encounters unrelated to lymphoma work-up in
asymptomatic or paucisymptomatic patients. Interestingly, anti-hepatitis C virus (HCV)
antibodies were more prevalent in patients with splenic FL compared with nodal FL with
splenic infiltration in a study of 17 cases [18].
4. Morphologic Findings
FL is morphologically composed of a heterogeneous lymphoid proliferation including
small/medium sized cleaved cells with inconspicuous nucleoli (centrocytes) and larger
cells with round/oval/convoluted vesicular nuclei, membrane bound nucleoli and visible
cytoplasm (centroblasts) admixed in various proportions (Figure 1). Current grading (based
on the average frequency of centroblasts from at least 10 high power fields) includes two
tiers: low-grade/grade 1–2 FL (with less than 16 centroblasts) and high-grade/grade 3 FL
(with 16 or more centroblasts). High-grade cases without centrocytes (grade 3B) tend to
behave more aggressively paralleling DLBCL.
Due to a dearth of studies, it is uncertain if PSFL has unique morphologic features.
Mollejo et al. analyzed 32 cases of FL in the spleen including an undetermined number of
PSFL [22]. However, most cases (18) represented low-grade disease, and the cohort was
divided according to expression of BCL2 (see the Immunophenotypic Findings). Regardless
of grading, all cases showed a white pulp predominant micronodular pattern, but some
cases also showed red pulp extension [22]. Howard et al. examined 16 cases of splenic
lymphoma in which up to 10 cases represented PFSL, identifying two histological patterns
irrespectively of the origin of the lymphoma (primary versus secondary) [15]. The first
pattern demonstrated distortion of the normal splenic architecture with packed neoplas-
tic follicles/nodules and some interfollicular proliferation. The second pattern showed
preserved splenic architecture with subtle white pulp expansion and an intact red pulp.
Interestingly, all six cases with intact architecture represented low-grade disease, which
could have been misinterpreted as reactive follicular hyperplasia [17]. Lastly, Shimono et al.
studied 17 patients with PSFL and 153 controls with nodal FL. Splenic macronodular le-
sions (larger than 3 cm) were less frequent in patients with nodal FL; however, architectural
differences or histologic grade stratification were not highlighted in this report [18].
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Figure 1. (A,B) PSFL in the white pulp of the spleen (H&E, 40× and 100×, respectively). (C) Interphase between nodular 
white pulp with lymphomatous involvement and red pulp without lymphoma (H&E, 200×), (D) Lymphoma cells com-
posed mainly of centrocytes (H&E, 400×). 
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5. Immunophenotypic Findings 
Like other mature B cell neoplasms, FL expresses pan-B cell antigens (CD19, CD22, 
CD79a and PAX5), and is also by definition positive for germinal center markers, such as 
BCL6, HGAL and LMO2. Accordingly, splenic FL almost always co-expresses CD20 and 
BCL6 (Figure 2) [17,22]. However, BCL6 negativity may be observed in high-grade FL [26], 
and this marker is frequently downregulated in the spleen [27] 
Figure 1. (A,B) PSFL in the white pulp of the spleen (H&E, 40× and 100×, respectively). (C) Interphase between nodular
white pulp with lymphomatous involvement and red pulp without lymphoma (H&E, 200×), (D) Lymphoma cells composed
mainly of centrocytes (H&E, 400×).
5. Immunophenotypic Findings
Like other mature B cell neoplasms, FL expresses pan-B cell antigens (CD19, CD22,
CD79a and PAX5), and is also by definition positive for germinal center markers, such as
BCL6, HGAL and LMO2. Accordingly, splenic FL almost always co-expresses CD20 and
BCL6 (Figure 2) [17,22]. However, BCL6 negativity may be observed in high-grade FL [26],
and this marker is frequently downregulated in the spleen [27].
In addition, BCL2 co-expression is variable. It is present in the vast majority of low-
grade cases but may be absent in higher grade FL [22]. Similarly, BCL2 expression fluctuates
depending on the topography of FL [9,28], which reflects on splenic FL. In a study of 32
cases of splenic FL, BCL2 was reported positive in 37.5%, mostly representing PSFL [22].
Other studies demonstrated BCL2 expression in 82.4% [18] and 100% of PSFL [17]. Notably,
BCL2 expression may correlate with prognosis, since negative cases were enriched for
higher grade morphology (including five cases transformed to DLBCL) when compared
with BCL2-positive cases [22]. CD10 is also expressed in most PSFL ranging from 58.1% [22]
to 100% of cases in published series [18]. MUM-1 expression was detected only in 0% to
13% of cases [18,22]. Newer germinal center B cell markers have been developed, including
HGAL and LMO2, which are not site specific. In a study with 13 cases of FL in the spleen,
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these markers were reported to be less sensitive than CD10, limiting their diagnostic utility
in splenic tissue [29]. CD43 is generally negative in FL, and therefore immunoreactivity
for this marker in the absence of expression of germinal center antigens may preclude the
diagnosis of PSFL [30].




Figure 2. Immunohistochemistry showing FL cells strongly positive for CD20 (A), CD10 (B), BCL6 (C) and BCL2 (D) (All 
at 400×). 
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lished in this lymphoma [31]. A study of 17 patients reported a significant association with 
HCV infection in PSFL versus nodal FL, but immunohistochemistry was not performed 
to detect viral protein expression in tumor cells, and an etiopathogenic relationship was 
not further investigated [18] 
Figure 2. Immunohistochemistry showing FL cells strongly positive for CD20 (A), CD10 (B), BCL6 (C) and BCL2 (D) (All
at 400×).
Finally, increased seropositivity for HCV has been detec ed in many types of mature
B cell lymphoma, including FL, but a d finite viral pathogen c ole has not been established
in this lymphoma [31]. A study of 17 patients reported a significant asso iatio with HCV
infection in PSFL versus nodal FL, but immunoh stochemistry was not performed to detect
viral prot in expression in tumor cells, and an et pathogenic relationship was not further
investigated [18]
Eme ging and historic data c rroborates that incorporation o Ki-67 pr liferation ind x
serves as an adjunct prognostic indicator in FL by facilitating centrobla identification,
and by acting as an independent progre sion free urvival (PFS) marker u coupled from
histologic grading [32–34].
6. Genetic Findings
Limited studies have been performed on genetic profiling of PSFL, and a systematic
co parison with nodal FL has not been published. Various chromoso al alterations (most
commonly loss of 1p, 6p, 10q and 17p; or gains of 1, 6p, 7, 8, 12q, X and 18q) are seen in FL [9].
Two independent studies reported a high degree of overlap between nodal and splenic
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FL regarding pathological and cytogenetic features [17,18]. The characteristic t(14;18)
translocation juxtaposing IGH and BCL2 is present in approximately 90% of low-grade
FL [9], and shows a good correlation with BCL2 expression by immunohistochemistry [35].
Interestingly, Mollejo et al. reported that 50% of PSFL expressing BCL2 also exhibit
the IGH/BCL2 translocation and represent predominantly low-grade histology [22]. Of
note, BCL6 rearrangements, which can be present in DLBCL, were absent in PSFL [22].
Another study using conventional fluorescent in situ hybridization, detected IGH/BCL2
translocations in 91% of 11 cases, and a complex cryptic 3-way translocation involving
BCL6, IGH and 11q (excluding CCND1) in one additional case [17]. Shimono et al. also
found genetic similarity (based in IGH-BCL2, NOTCH1 and NOTCH2 analysis) between
nodal and splenic lymphoma in a series studying 17 patients with PSFL [18]. Splenomegaly,
female sex, and absence of IGH/BCL2 translocation are associated with higher frequency
of NOTCH mutations in FL [36]. However, NOTCH1/NOTCH2 alterations were detected
only in 6.3% of 11 cases in a small study [36]. Therefore, additional research is necessary
to determine if splenic FL has a unique molecular landscape selectively affecting genes
commonly mutated in FL, such as: BCL2, KMT2D (MLL2), TNFRSF14, EZH2, EPHA7,
CREBBP, BCL6 and TNFAIP3 [9].
7. Diagnostic Work-Up
Comprehensive clinical and laboratory assessment (including viral hepatitis and
human immunodeficiency virus tests), imaging studies (ideally CT and PET/CT) and bone
marrow/peripheral blood evaluation (including multiparametric immunophenotyping)
are strongly recommended if splenic FL is suspected during the clinical investigation of
isolated splenomegaly [37]. Ultrasound imaging has also been used in the diagnostic
workup with an overall sensitivity of approximately 50% [38]. Flow cytometry is extremely
useful in the setting of PSFL due its high sensitivity to detect minimal involvement of
peripheral blood and/or bone marrow. Similarly, ancillary cytogenetic and molecular
diagnostic techniques may be invaluable to identify the t(14;18) translocation and other
genetic alterations. Ultimately, histologic examination of spleen may be necessary, since
FL is usually cytologically heterogeneous, and sampling errors due to inadequate tissue
(particularly from core biopsies) may result in misdiagnosis. For instance, a significant
number of DLBCL may selectively involve the bone marrow with clones composed only
by small cells, mimicking low-grade lymphoma [39]. Similarly, splenic core biopsies may
incorrectly suggest the diagnosis of PSFL (or DLBCL) due to sampling bias in heterogeneous
tumors. Therefore, splenectomy may eventually be necessary for a precise diagnosis of
lymphoma, including PSFL.
8. Differential Diagnosis
The combination of morphology and immunophenotype generally yields a categorical
diagnosis and subtyping of B cell lymphoma. The differential diagnosis of FL is narrow
after excluding high-grade CD10-positive lymphomas, such as DLBCL and BL, which are
beyond the scope of this review. Clinicopathological correlation is necessary to determine
if FL represents primary or secondary disease. Morphologically, PSFL is most frequently
composed by small cells (centrocytes) without sheets of larger cells. In contrast, DLBCL and
BL show sheets of large- and medium-sized cells, respectively. Furthermore, while PSFL,
BL and DLBCL predominantly involve white pulp, DLBCL may spill into red pulp [40].
Interestingly, BL presenting as PSL would be very unusual [41].
Excellent reviews are available to guide a practical immunophenotypic subclassifica-
tion of B cell lymphoma [42,43], which are applicable to PSFL. Interestingly, a hierarchical
model based on binary expression of CD5 and CD10 has also been proposed using machine
learning technology [44]. In summary, FL is usually not a diagnostic dilemma by virtue
of observing a distinctive immunophenotype (positivity for CD10, BCL2, BCL6, HGAL,
LMO2, GCET1 and Stathmin, and negativity for CD5, CD43 and CyclinD1) in the correct
morphologic setting (see the Morphologic Findings). However, if a rare CD10-negative FL
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is considered in the differential diagnosis, additional markers such as IRTA and MNDA
(which are commonly positive in MZL and negative in FL) may be necessary [45]. Other
CD5/CD10-double negative low-grade B cell lymphomas may very infrequently show
aberrant expression of CD10, posing a diagnostic challenge to differentiate from FL (par-
ticularly with splenic presentation), as covered extensively elsewhere and in this review
series [42–46] (and cross referencing Auerbach, Gomes and Aggarwal’s papers). For ex-
ample, HCL can express CD10 [7], but its triple positivity for CD25, CD103 and CD123
together with the absence of BCL6 expression (usually positive in FL), and the presence of
BRAF V600E alteration, should permit clear segregation from other small B cell lymphomas,
including PSFL [7]. Similar diagnostic capacity can be attributed to the MYD88 L265P
mutation in combination with an IgM gammopathy to correctly identify LPL [47].
9. Treatment and Prognosis
Treatment of splenic lymphomas is ascribed to its lineage. Based on a few available
studies it has been suggested to treat patients with splenic lymphomas with regimens
developed for nodal lymphomas, which is particularly true for FL. However, long term
outcome data are unavailable given the rarity of splenic lymphomas. Consequently, specific
treatment modalities are not formally recommended for PSFL yet [37].
HCV infection has been more frequently described in PSFL than in nodal FL [18], and
anti-viral therapy alone can induce remission of lymphoproliferative disorders [48–50],
suggesting this option for PSFL.
Stage I PSFL diagnosed on splenectomy specimen could be subjected to an active
observation/expectant management strategy, mirroring guidelines for nodal FL stage I
treated with complete surgical removal of the affected lymph nodes [37]. Long treatment-
free intervals may be achieved by this approach, while minimizing therapy-related adverse
effects. A recent large case series of splenic lymphomas undergoing splenectomy demon-
strated that additional chemotherapy after surgery did not impact overall survival (OS)
in FL [23], further supporting the practice of expectant management. However, the man-
agement of stage I nodal FL remains mired in controversy. While current guidelines still
recommend localized radiotherapy, heterogenous alternatives (ranging from vigilance to
adjuvant Rituximab monotherapy or immunochemotherapy) are used as evident from
prospective observational studies and real-world series [51]. The combination of radiother-
apy with systemic treatments (chemotherapy or immunochemotherapy) has been shown to
prolong PFS but not OS, and the decision to offer additional treatment remains both patient
and physician dependent [52,53]. These concepts have been applied to early PSFL. On
the other hand, PSFL presenting with combinations of liver, bone marrow and peripheral
blood involvement are expected to behave like advanced FL (stage IV), and the therapeutic
choices range from active observation (for low tumor burden asymptomatic disease) to
first line immunochemotherapy (for high tumor burden symptomatic disease) [37]. Com-
monly, combinations of Rituximab with Bendamustine, CHOP or CVP have been used as
first line regimens [54,55]. Recently, substituting Rituximab for Obinutuzumab (a type II
glycoengineered humanized anti-CD20 monoclonal antibody) in similar chemotherapy
combinations was shown to prolong PFS without impacting OS [56].
Maintenance regimens with anti-CD20 monoclonal antibodies have been applied by
several investigators, again prolonging PFS but not OS [57]. The efficacy of maintenance
regimens for advanced leukemic disease (as is common in stage IV PSFL) deserves inves-
tigation, since lymphocytosis at presentation implies poor prognosis in nodal FL [58,59].
Treatment of relapsed PSFL can also be modelled on nodal FL, where management is influ-
enced by multiple, patient and disease related factors, including the interval between diag-
nosis and relapse, and documentation of histologic transformation. A growing number of
signaling pathway-specific/non-chemotherapy agents and cellular therapies are becoming
available for FL, which could change the course of this still incurable disease [60,61]. How-
ever, the applicability of these new strategies to PSFL is unknown, and probably dependent
on further clarification of specific biological characteristics and pathogenic mechanisms.
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Conclusive data on prognostication of PSFL are not available yet. In the largest series
published to date, survival was similar to nodal FL using treatment options ranging splenec-
tomy alone to combined surgery and chemotherapy [22]. It is conceivable that the prognosis
of PSFL may be influenced by the stage of disease and prognostic scores usually applied
to nodal FL (namely the Follicular Lymphoma International Prognostic Index/FLIPI and
FLIP2) [62,63]. However, the clinical outcomes of patients with spleen-confined disease
have been similar to those of individuals with disseminated lymphoma [17], which may be
explained by a limited sample size.
When PFSL transforms to aggressive lymphoma, regimens for DLBCL (immuno-
chemotherapy with anti-CD20 antibodies and standard anthracycline-based chemotherapy
for at least four cycles in localized stages) are used achieving comparable results.
10. Conclusions
In conclusion, novel chemotherapy-free modalities emerging for other types of B cell
lymphoma will be adapted for splenic lymphomas, enabling improvements in the treat-
ment and prognosis of PSFL that may evolve in parallel with a more detailed biological
characterization of this rare entity.
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